BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/24/2026 7:03:48 AM | Browse: 1 | Download: 0
 |
Received |
|
2025-12-02 00:53 |
|
Peer-Review Started |
|
2025-12-03 09:20 |
|
First Decision by Editorial Office Director |
|
2025-12-24 10:14 |
|
Return for Revision |
|
2025-12-24 10:14 |
|
Revised |
|
2025-12-29 11:24 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-19 02:38 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-19 10:57 |
|
Articles in Press |
|
2026-01-19 10:57 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-15 08:19 |
|
Publish the Manuscript Online |
|
2026-07-24 07:03 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Xietu Hemu prescription: A novel therapeutic strategy for obesity and metabolic dysfunction-associated steatotic liver disease?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alessia Provera, Anteneh Nigussie Sheferaw, Emmanuel Kivumbi and Salvatore Sutti |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Salvatore Sutti, PhD, Principal Investigator, Professor, Department of Health Sciences, University of East Piedmont, Via Solaroli 17, Novara 28100, Italy. salvatore.sutti@med.uniupo.it |
| Key Words |
Traditional Chinese medicine; Xietu hemu prescription; Therapies; Metabolism; Liver; Metabolic dysfunction-associated steatohepatitis; Metabolic dysfunction-associated steatotic liver disease |
| Core Tip |
The study by Cheng et al provides new insights into how Xietu hemu prescription (XHP) may exert beneficial effects on obesity and metabolic dysfunction-associated steatotic liver disease through AMPK activation and leptin-mediated modulation of lipid metabolism. While promising, these findings should be interpreted with caution, as the specific metabolites responsible for the observed effects remain unclear, and the use of rat serum to treat human and murine cells introduces relevant translational limitations. Notably, XHP-derived metabolites may also influence inflammatory and survival pathways, including IL-17 and PI3K/AKT signaling, potentially broadening the therapeutic implications of XHP. Further studies are needed to validate these mechanisms in human systems, explore the anti-inflammatory potential of XHP, and identify its key active metabolites to enhance translational relevance. |
| Publish Date |
2026-07-24 07:03 |
| Citation |
Provera A, Sheferaw AN, Kivumbi E, Sutti S. Letter to the Editor: Xietu Hemu prescription: A novel therapeutic strategy for obesity and metabolic dysfunction-associated steatotic liver disease? World J Hepatol 2026; 18(7): 117126
|
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i7/117126.htm |
| DOI |
https://doi.org/10.4254/wjh.117126 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
